BNTX Stock Analysis: BioNTech SE | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 22.808m USD | 12M Return: -12.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 88.7M
Qual. Beats: 0
Rev. Trend: -68.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.7 years of data
Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.
BioNTech SE (NASDAQ: BNTX) is a Mainz, Germany-based biotechnology company founded in 2008 that develops and commercializes immunotherapies, primarily leveraging its mRNA technology platform. The company gained global prominence with BNT162, its mRNA vaccine targeting SARS-CoV-2, and has since built out a broad clinical pipeline spanning oncology and infectious diseases.
The oncology portfolio is the largest component, with multiple candidates in Phase II and Phase III trials across lung, breast, colorectal, ovarian, pancreatic, and other cancers. Lead late-stage assets include Gotistobart (non-small cell lung cancer), Pumitamig (small cell lung cancer, triple-negative breast cancer, and other solid tumors), Trastuzumab pamirtecan (metastatic breast cancer), BNT113 (HPV-related head and neck cancer), and Autogene cevumeran (colorectal cancer).
Beyond oncology, BioNTech is advancing infectious disease vaccines in earlier-stage trials targeting mpox (BNT166), tuberculosis (BNT164), malaria (BNT165), and combination SARS-CoV-2/influenza candidates. Listed on NASDAQ since its October 2019 IPO, the company operates within the GICS Health Care / Biotechnology sub-industry and runs a platform-based business model in which its mRNA technology is applied across multiple therapeutic areas rather than focused on a single indication.
- COVID vaccine revenue declines sharply as demand normalizes
- Phase III oncology readouts approach for lead mRNA candidates
- Large cash reserves deployed to fund R&D and strategic acquisitions
| Net Income: -1.26b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 11.87 > 1.0 |
| NWC/Revenue: 492.4% < 20% (prev 513.1%; Δ -20.67% < -1%) |
| CFO/TA 0.04 > 3% & CFO 858.0m > Net Income -1.26b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (252.9m) vs 12m ago 5.22% < -2% |
| Gross Margin: 73.17% > 18% (prev 79.39%; Δ -6.22% > 0.5%) |
| Asset Turnover: 13.24% > 50% (prev 12.97%; Δ 0.27% > 0%) |
| Interest Coverage Ratio: -82.16 > 6 (EBIT TTM -1.17b / Interest Expense TTM 14.2m) |
| A: 0.65 (Total Current Assets 15.5b - Total Current Liabilities 1.77b) / Total Assets 21.1b |
| B: 0.83 (Retained Earnings 17.4b / Total Assets 21.1b) |
| C: -0.06 (EBIT TTM -1.17b / Avg Total Assets 21.1b) |
| D: 7.87 (Book Value of Equity 18.7b / Total Liabilities 2.38b) |
| Altman-Z'' = 14.87 = AAA |
| DSRI: 0.59 (Receivables 612.8m/1.03b, Revenue 2.80b/2.75b) |
| GMI: 1.08 (GM 79.39% / 73.17%) |
| AQI: 0.99 (AQ_t 0.20 / AQ_t-1 0.20) |
| SGI: 1.02 (Revenue 2.80b / 2.75b) |
| TATA: -0.10 (NI -1.26b - CFO 858.0m) / TA 21.1b) |
| Beneish M = -3.29 (Cap -4..+1) = AA |
As of July 01, 2026, the stock is trading at USD 93.05 with a total of 559,788 shares traded. Over the past week, the price has changed by +2.68%, over one month by +1.47%, over three months by +4.69% and over the past year by -12.60%.
Current recommended Stop Loss: 89.80 (which is 3.5% or 1.2 ATR below the current price).
BioNTech SE has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy BNTX.
- StrongBuy: 13
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 121.9 | 31% |
Market Cap EUR = 20.0b (22.8b USD * 0.8765 USD.EUR)
P/E Forward = 7.0373
P/S = 8.1305
P/B = 1.0338
P/EG = 0.046
Revenue TTM = 2.80b EUR
EBIT TTM = -1.17b EUR
EBITDA TTM = -704.7m EUR
Long Term Debt = 246.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 56.8m EUR (from shortTermDebt, last quarter)
Debt = 528.5m EUR (from shortLongTermDebtTotal, last quarter) + Leases 225.4m
Net Debt = -14.1b EUR (calculated: Debt 528.5m - CCE 14.7b)
Enterprise Value = 5.87b EUR (20.0b + Debt 528.5m - CCE 14.7b)
Interest Coverage Ratio = -82.16 (Ebit TTM -1.17b / Interest Expense TTM 14.2m)
EV/FCF = 4.65x (Enterprise Value 5.87b / FCF TTM 1.26b)
FCF Yield = 21.53% (FCF TTM 1.26b / Enterprise Value 5.87b)
FCF Margin = 45.14% (FCF TTM 1.26b / Revenue TTM 2.80b)
Net Margin = -44.95% (Net Income TTM -1.26b / Revenue TTM 2.80b)
Gross Margin = 73.17% ((Revenue TTM 2.80b - Cost of Revenue TTM 750.7m) / Revenue TTM)
Gross Margin QoQ = -63.17% (prev 63.27%)
Tobins Q-Ratio = 0.28 (Enterprise Value 5.87b / Total Assets 21.1b)
Interest Expense / Debt = 2.69% (Interest Expense 14.2m / Debt 528.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -921.5m (EBIT -1.17b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.80 (Total Current Assets 15.5b / Total Current Liabilities 1.77b)
Debt / Equity = 0.03 (Debt 528.5m / totalStockholderEquity, last quarter 18.7b)
Debt / EBITDA = 20.04 (negative EBITDA) (Net Debt -14.1b / EBITDA -704.7m)
Debt / FCF = -11.18 (Net Debt -14.1b / FCF TTM 1.26b)
Total Stockholder Equity = 18.7b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.95% (Net Income -1.26b / Total Assets 21.1b)
RoE = -6.72% (Net Income TTM -1.26b / Total Stockholder Equity 18.7b)
RoCE = -6.15% (EBIT -1.17b / Capital Employed (Equity 18.7b + L.T.Debt 246.1m))
RoIC = -4.79% (negative operating profit) (NOPAT -921.5m / Invested Capital 19.2b)
WACC = 9.39% (E(20.0b)/V(20.5b) * Re(9.58%) + D(528.5m)/V(20.5b) * Rd(2.69%) * (1-Tc(0.21)))
Discount Rate = 9.58% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 28.89 | Cagr: 2.16%
[DCF] Terminal Value 71.88% ; FCFF base≈1.26b ; Y1≈1.27b ; Y5≈1.34b
[DCF] Fair Price = 126.1 (EV 17.8b - Net Debt -14.1b = Equity 31.9b / Shares 252.9m; r=9.39% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.07 | # QB: 0
Revenue Correlation: -68.71 | Revenue CAGR: -26.21% | SUE: -0.12 | # QB: 0
EPS next Quarter (2026-09-30): EPS=0.66 | Chg30d=-38.04% | Revisions=-20% | Analysts=3
EPS current Year (2026-12-31): EPS=-4.60 | Chg30d=+1.23% | Revisions=+11% | GrowthEPS=-859.2% | GrowthRev=-24.5%
EPS next Year (2027-12-31): EPS=-4.43 | Chg30d=+5.38% | Revisions=+11% | GrowthEPS=+3.9% | GrowthRev=+3.0%
[Analyst] Revisions Ratio: -20%